Background
Methods
Number of cases | Total % | Valid % | ||
---|---|---|---|---|
Age |
40 ≥
| 29 | 24.2 | 24.2 |
40 <
| 91 | 75.8 | 75.8 | |
cT |
T1
| 19 | 15.8 | 15.8 |
T2
| 73 | 60.8 | 60.8 | |
T3
| 15 | 12.5 | 12.5 | |
T4
| 13 | 10.8 | 10.8 | |
pT |
pT0
| 20 | 16.7 | 18.7 |
pT1
| 40 | 33.3 | 37.4 | |
pT2
| 34 | 28.3 | 31.8 | |
pT3
| 9 | 7.5 | 8.4 | |
pT4
| 4 | 3.3 | 3.7 | |
Unknown
| 13 | 10.8 | ||
cN |
N0
| 46 | 38.3 | 40.4 |
N1
| 55 | 45.8 | 48.3 | |
N2
| 9 | 7.5 | 7.9 | |
N3
| 4 | 3.3 | 3.5 | |
Nx
| 6 | 5.0 | ||
pN |
pN0
| 51 | 42.5 | 48.1 |
pN1
| 36 | 30 | 33.9 | |
pN2
| 13 | 10.8 | 12.3 | |
pN3
| 6 | 5 | 5.7 | |
Nx
| 14 | 11.7 | ||
Grade |
1
| 1 | 0.8 | 0.9 |
2
| 46 | 38.3 | 41.8 | |
3
| 63 | 52.5 | 57.3 | |
Unknown
| 10 | 8.3 | ||
ER status |
Positive
| 80 | 66.7 | 66.7 |
Negative
| 40 | 33.3 | 33.3 | |
PgR status |
20% >
| 8 | 6.7 | 6.7 |
20% ≤
| 49 | 40.8 | 41.2 | |
Negative
| 62 | 51.7 | 52.1 | |
Unknown
| 1 | 0.8 | ||
HER2 status |
Positive
| 41 | 34.2 | 34.2 |
Negative
| 79 | 65.8 | 65.8 | |
Histological type |
Lobular
| 6 | 5.0 | 5.1 |
IBC NOS
| 112 | 93.3 | 94.9 | |
Other/Unknown
| 2 | 1.7 | ||
Molecular subtype |
Luminal A
| 15 | 12.5 | 12.5 |
Luminal B/HER2-
| 38 | 31.7 | 31.7 | |
Luminal B/HER2+
| 27 | 22.5 | 22.5 | |
HER2+
| 14 | 11.7 | 11.7 | |
Triple-negative
| 26 | 21.7 | 21.7 | |
Response |
Complete
| 23 | 19.2 | 19.2 |
Partial
| 73 | 60.8 | 60.8 | |
Non-responder
| 24 | 20.0 | 20.0 | |
Antracyclines |
Yes
| 88 | 73.3 | 73.3 |
No
| 32 | 26.7 | 26.7 | |
Taxanes |
Yes
| 99 | 82.5 | 82.5 |
No
| 21 | 17.5 | 17.5 | |
Platinum |
Yes
| 31 | 25.83 | 25.83 |
No
| 89 | 74.16 | 74.16 | |
Trastuzumab |
Yes
| 12 | 10.0 | 10.0 |
No
| 108 | 90.0 | 90.0 |
Immunohistochemical analysis
Clinical outcome assessment
Statistical analysis
Results
Baseline clinical and pathological data
Therapy response category | N | HR status (%) | p1
| Average age at diagnosis (year ± SD) | p2
| |||
---|---|---|---|---|---|---|---|---|
HR+
|
HR−
|
HR+
|
HR−
|
all
| ||||
pCR | 23 | 5 (21.7) | 18 (78.3) | <0.001 | 44.2 ± 12.6 | 46.4 ± 13.8 | 46.0 ± 13.3 | 0.008 |
pPR | 73 | 55 (75.3) | 18 (24.7) | 50.0 ± 11.0 | 52.3 ± 12.8 | 50.4 ± 11.4 | ||
pNR | 24 | 20 (83.3) | 4 (16.7) | 55.9 ± 10.7 | 53.3 ± 14.5 | 55.6 ± 11.0 |
Defining cut-off points for Ki-67expression in the pCR and pNR groups
Defining cut-off points for Ki-67 expression based on Survival (DMFS and OS)
Association between Ki-67, Subtype and Pathological Response
Prognostic potential of Ki-67 status, Subtype and Pathological Response (DMFS and OS)
Prognostic factor | Multivariate Cox regression regarding distant metastasis-free survival (n = 120) | Multivariate Cox regression analysis regarding overall survival (n = 120) | Multivariate Cox regression without Luminal-A cases regarding distant metastasis-free survival (n = 105) | Multivariate Cox regression without Luminal-A cases regarding overall survival (n = 105) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI |
p-value | HR | 95% CI |
p-value | HR | 95% CI |
p-value | HR | 95% CI |
p-value | |
Age | 0.964 | 0.653–1.487 | 0.919 | 1.532 | 0.950–2.470 | 0.080 | 0.933 | 0.565–1.540 | 0.787 | 1.477 | 0.928–2.350 | 0.100 |
pT | 2.397 | 1.094–5.252 | 0.029 | 1.931 | 0.914–4.082 | 0.085 | 1.812 | 0.914–3.592 | 0.086 | 1.903 | 0.895–4.046 | 0.079 |
cT | 0.771 | 0.356–1.671 | 0.510 | 1.173 | 0.505–2.726 | 0.711 | 0.831 | 0.341–2.024 | 0.685 | 1.176 | 0.507–2.724 | 0.706 |
IHC Subtype | 1.676 | 0.436–6.439 | 0.452 | 2.230 | 1.231–4.043 | 0.008 | 3.263 | 0.369–22.823 | 0.287 | 2.135 | 1.202–3.785 | 0.009 |
Histological grade | 1.280 | 0.415–3.945 | 0.667 | 1.641 | 0.559–4.815 | 0.367 | 1.381 | 0.394–4.836 | 0.614 | 1.278 | 0.453–3.605 | 0.643 |
pN | 1.146 | 0.681–1.929 | 0.607 | 1.478 | 0.881–2.479 | 0.139 | 1.334 | 0.765–2.325 | 0.309 | 1.417 | 0.874–2.296 | 0.157 |
cN | 1.641 | 0.724–3.717 | 0.235 | 1.502 | 0.694–3.253 | 0.302 | 1.980 | 0.837–4.682 | 0.120 | 1.485 | 0.685–3.219 | 0.317 |
Hormone receptor status | 0.905 | 0.061–13.456 | 0.942 | 0.561 | 0.201–1.565 | 0.270 | 2.833 | 0.244–20.808 | 0.623 | 0.784 | 0.289–2.130 | 0.633 |
Pathological response | 0.851 | 0.263–2.749 | 0.787 | 1.056 | 0.376–2.965 | 0.918 | 0.814 | 0.217–3.049 | 0.760 | 1.899 | 0.300–2.694 | 0.850 |
Ki-67 LI_D15% | 1.628 | 0.288–9.209 | 0.581 | 2.022 | 0.373–10.962 | 0.414 | 2.105 | 0.288–15.843 | 0.353 | 1.568 | 0.287–8.570 | 0.604 |
Ki-67 LI_D20% | 2.575 | 0.511–12.962 | 0.251 | 2.847 | 0.528–15.341 | 0.223 | 3.864 | 0.495–28.809 | 0.175 | 2.338 | 0.434–12.604 | 0.323 |
Ki-67 LI_D30% | 1.217 | 0.353–4.201 | 0.756 | 5.286 | 1.189–23.488 | 0.029 | 1.361 | 0.352–5.255 | 0.655 | 4.850 | 1.089–18.379 | 0.038 |